Illumina has partnered with Vitrolife to sell our preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD) products in Europe, Middle East, and Africa (EMEA) and the Americas. Vitrolife expects to take customer orders starting December 1 and to transition all sales and support in early 2019. Both Illumina and Vitrolife are committed to ensuring a seamless transition.
The HumanKaryomap-12 DNA Analysis Kit is a comprehensive genome-wide test available at the single-cell level. It provides insight into the inheritance of single-gene defects.
This BeadChip array targets ~300,000 of the most informative markers in the genome for efficient genome-wide coverage1. Karyomapping uses biomarkers within the genome to assess the likelihood of an embryo carrying a gene variant involved in a single-gene disorder.
Preimplantation genetic diagnosis (PGD) with karyomapping enables screening of embryos for the likelihood of carrying the defective gene prior to transfer to the uterus. This method uses SNP (single nucleotide polymorphisms) array technology to confirm the presence or absence of a specific allele.
Scientists used the HumanKaryomap-12 Array to identify balanced translocation carriers and translocation abnormalities in blastocysts for informed IVF embryo selection.
Read InterviewAn Introduction to Illumina Next-Generation Sequencing Technology for HLA Analysis
White Paper | PDF< 1 MB
The SureMDA Amplification System has been discontinued. The REPLI-g Single Cell Kit (QIAGEN) is the suggested replacement for use in the Infinium Karyomapping assay. Illumina remains committed to providing customers with high-quality support and service.
A fully validated next-generation sequencing solution that provides accurate chromosome screening for selection of embryos most likely to be euploid.